Experimental cell therapy targets tough blood disorder
NCT ID NCT07075484
First seen Mar 04, 2026 · Last updated Apr 28, 2026 · Updated 6 times
Summary
This early-stage trial tested a new cell therapy called YTS109 in 7 people with a severe type of autoimmune anemia that did not get better after at least 3 other treatments. The goal was to see if the therapy is safe and can help control the disease. Researchers used special immune cells (STAR-T cells) to try to stop the body from attacking its own red blood cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.